Deviation of type I and type II T cells and its negative effect on hematopoiesis in myelodysplastic syndrome

International Journal of Laboratory Hematology

Volumn 30, Issue 5, 2008, Pages 390-399

  Wu, L ^a   Li, X ^a   Chang, C ^a   Ying, S ^a   He, Q ^a   Pu, Q ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cytokines; Myelodysplastic syndrome; T cells

Indexed keywords

CYTOKINE; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; HELPER CELL; HEMATOPOIESIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MYELODYSPLASTIC SYNDROME; NICK END LABELING; PRIORITY JOURNAL; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; SCORING SYSTEM; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; BONE MARROW CELLS; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; HEMATOPOIESIS; HUMANS; IN SITU NICK-END LABELING; INTERFERON-GAMMA; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; T-LYMPHOCYTE SUBSETS; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 51349100864     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2007.00970.x     Document Type: Article

References (22)

1. Baumann I., Scheid C., Koref M.S., Swindell R., Stern P. Testa N.G. (2002) Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic syndrome. Experimental Hematology 30, 1405 1411.
2. Gersuk G.M., Beckham C., Loken M.R., Kiener P., Anderson J.E., Farrand A., Troutt A.B., Ledbetter J.A. Deeg H.J. (1998) A role for tumour necrosis factor-a, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. British Journal of Haematology 103, 176 188.
3. Giannakoulas N.C., Karakantza M., Theodorou G.L., Pagoni M., Galanopoulos A., Kakagianni T., Kouraklis-Symeonidis A., Matsouka P., Maniatis A. Zoumbos N.C. (2004) Clinical relevance of balance between type 1 and type 2 immune responses of lymphocyte subpopulations in aplastic anaemia patients. British Journal Haematology 24, 97 105.
4. Greenberg P., Cox C., Le Beau M.M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G. Bennett J. (1997) International prognosis scoring system (IPSS) for evaluating prognosis in myelodysplastic syndrome. Blood 89, 2079 2088.
5. Harris N., Jaffe E., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J., Lister T.A. Bloomfield C.D. (1999) WHO classification of neoplastic diseases of the hematopietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Article House, Virginia, November 1997. Journal of Clinical Oncology 17, 3835 3849.
6. Invernizzi R., Pecci A., Bellotti L. Ascari E. (2001) Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes. Leukaemia & Lymphoma 42, 481 489.
7. Itoh M., Yago K., Shimada H. Tohyama K. (2002) Reversible acceleration of disease progression following cyclosporin A treatment in a patient with myelodysplastic syndrome. International Journal of Hematology 75, 302 304.
8. Jung T., Schauer U., Heuser C., Neumann C. Rieger C. (1993) Detection of intracellular cytokines by flow cytometry. Journal of Immunological Methods 159, 197 207.
9. Kitagawa M., Saito I., Kuwata T., Yoshida S., Yamaguchi S., Takahashi M., Tanizawa T., Kamiyama R. Hirokawa K. (1997) Overexpression of tumor necrosis factor (TNF)-alpha and interferon (INF)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 11, 2049 2054.
10. Li X., Bryant E. Deeg H.J. (2004) Simultaneous demonstration of clonal chromosome abnormalities and apoptosis in individual marrow cells in myelodysplastic syndrome. International Journal of Hematology 80, 140 145.
11. Luraschi A., Saglietti G., Fedeli P., Gioria A., Della Vedova A., Ferrari V. Borgotti P. (1994) Immunological indices in myelodysplastic syndromes. Minerva Medica 85, 145 153.
12. Mossman T.R., Li L. Sad S. (1997) Function of CD8 T-cell subsets secreting different cytokine patterns. Seminars in Immunology 9, 87 92.
13. Plasilova M., Zivny J., Jelinek J., Neuwirtova R., Cermak J., Necas E., Andera L. Stopka T. (2002) TRAIL (Apo2 L) suppresses growth of primary human leukemia and myelodysplastic syndromes. Leukemia 16, 67 73.
14. Raza A., Gezer S., Mundle S., Gao X.Z., Alvi S., Borok R., Rifkin S., Iftikhar A., Shetty V. Parcharidou A. (1995) Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86, 268 276.
15. Romagnami S. (1991) Human Th1 and Th2 subsets: doubt no more. Immunology Today 12, 256 257.
16. Saunthararajah Y., Nakamura R., Nam J.M., Robyn J., Loberiza F., Maciejewski J.P., Simonis T., Molldrem J., Young N.S. Barrett A.J. (2002) HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100, 1570 1574.
17. Saunthararajah Y., Nakamura R., Wesley R., Wang Q.J. Barrett A.J. (2003) A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 102, 3025 3027.
18. Shimamoto T., Tohyama K., Okamoto T., Uchiyama T., Mori H., Tomonaga M., Asano Y., Niho Y., Teramura M., Mizoguchi H., Omine M. Ohyashiki K. (2003) Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. Leukemia Research 27, 783 788.
19. Sloand E.M., Mainwaring L., Fuhrer M., Ramkissoon S., Risitano A.M., Keyvanafar K., Lu J., Basu A., Barrett A.J. Young N.S. (2005) Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 106, 841 851.
20. Stadler M., Germing U., Kliche K.O., Josten K.M., Kuse R., Hofmann W.K., Schrezenmeier H., Novotny J., Anders O., Eimermacher H., Verbeek W., Kreipe H.H., Heimpel H., Aul C. Ganser A. (2004) A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18, 460 465.
21. suda H. Yamasaki H. (2000) Type I and type II T-cell profiles in aplastic anemia and refractory anemia. American Journal of Hematology 64, 271 274.
22. Yazji S., Gile F.J., Tsimberidou A.M., Estey E.H., Kantarjian H.M., O'Brien S.A. Kurzrock R. (2003) Antithymocyte globulin (ATG) -based therapy in patients with myelodysplastic syndromes. Leukemia 17, 2101 2106.